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Objectives The aim of this study was to confirm the generalizability of the conclusions of the STICH (Surgical Treatment for
Ischemic Heart Failure) trial.
Background Surgical ventricular reconstruction (SVR) added to coronary artery bypass grafting (CABG) did not decrease death
or cardiac hospitalization in STICH patients randomized to CABG with (n  501) or without (n  499) SVR.
Methods Baseline clinical characteristics of 1,000 STICH SVR hypothesis patients and 1,036 STICH-eligible Society of Tho-
racic Surgeons (STS) National Cardiac Database patients undergoing CABG plus SVR were entered into a multi-
variate model equation to predict a mortality that placed these 2,036 patients in 1 of 32 risk at randomization
(RAR) groups. The number of patients in each RAR group profiled the risk of STICH treatment arms and of STICH
and STS STICH-eligible patients.
Results That 85% of the 1,000 STICH patients known to have no significant differences in baseline characteristics be-
tween the 2 treatment arms shared the same RAR group suggests that the RAR methodology has sufficient ac-
curacy to compare RAR profiles of STICH and STS patients. RAR group was shared by 1,522 of 2,036 STICH and
STS STICH-eligible patients (75%) who underwent CABG plus SVR. Differences in baseline characteristics respon-
sible for more low-risk STICH patients and more high-risk STS patients were modest. Cox proportional hazard
ratios of 1,000 STICH patients in 3 RAR groups suggested by STICH and STS RAR differences showed no differ-
ential treatment effect on survival across the low-, intermediate-, and high-risk groups.
Conclusions The STICH conclusion of no benefit from adding SVR to CABG applies to a broad spectrum of CABG-eligible pa-
tients with ischemic cardiomyopathy. (Comparison of Surgical and Medical Treatment for Congestive Heart Fail-
ure and Coronary Artery Disease; NCT00023595) (J Am Coll Cardiol 2010;56:499–507) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.054r
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Lurgical ventricular reconstruction (SVR) is a technical
efinement of left ventricular (LV) aneurysmectomy. The
bjective of SVR is to arrest or reverse progressive global
ardiac dilation and heart failure by acutely reducing LV
olume and wall stress and thereby minimize the deleterious
ffect of regional dysfunction on total cardiac performance.
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See page 508
valuate whether adding SVR to coronary artery bypass
rafting (CABG) benefited patients with dominant anterior
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ticipating patients were random-
ized to CABG alone (n  499)
or CABG plus SVR (n  501)
and followed for a median of 48
months for the primary outcome
of death or cardiac hospitaliza-
tion (2). Cardiac symptoms and
exercise tolerance improved sig-
nificantly from baseline to a sim-
ilar degree in both groups after
surgery. Although CABG plus
SVR reduced mean LV end-
systolic and end-diastolic vol-
umes more than CABG alone,
the primary outcome of death or
cardiac hospitalization did not
iffer between the 2 treatment groups (3). This result
urprised many cardiovascular specialists, who raised ques-
ions regarding whether the results of the STICH trial
hould be generalized to the broad spectrum of patients with
schemic cardiomyopathy (4).
Patient eligibility for the STICH trial required coronary
rtery disease amenable to CABG and left ventricular
jection fraction (LVEF) 0.35. SVR eligibility required
ominant anterior akinesia or dyskinesia amenable to
ABG. Patients considered to be SVR candidates who did
ot need CABG and patients judged as definitely needing
ABG plus SVR were not eligible for STICH. SVR-
ligible patients could have been randomized in STICH
tratum C to CABG with or without SVR. All stratum C
atients were analyzed only in the STICH SVR hypothesis
ohort. Patients eligible for evidence-based medical therapy
lone and for CABG with or without SVR were random-
zed among these 3 treatment options in stratum B. Stratum
patients had a 2 in 3 chance of randomization to the
TICH SVR hypothesis. Stratum B patients randomized to
vidence-based medical therapy alone were compared with
ABG in the surgical revascularization hypothesis. Stratum
patients randomized to CABG provided primary out-
ome data for both hypotheses. Stratum B patients random-
zed to CABG plus SVR were only analyzed in the STICH
VR hypothesis.
Patients were judged “amenable to CABG” on the
uitability of coronary stenoses for bypass and the benefit
xpected from surgical revascularization. Patients were
udged “amenable to SVR” on the extent and severity of
nterior regional dysfunction in the context of global dys-
unction. Patients with anterior dysfunction as an equivalent
omponent of global dysfunction were not SVR candidates.
ide variation was apparent in the decisions cardiovascular
pecialists made about which patients were amenable to
ndergo either or both procedures. However, coronary
rtery disease and LV functional assessments used to define
ligibility for operations were always considered in the
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
DDCD  Duke Databank for
Cardiovascular Diseases
LV  left ventricular
LVEF  left ventricular
ejection fraction
RAR  risk at
randomization
STS  Society of Thoracic
Surgeons
SVR  surgical ventricular
reconstructionontext of overall baseline clinical risk. The rationale for gpecific randomization decisions at clinical sites cannot be
nown. However, the baseline characteristics of the patient
opulation resulting from these 1,000 equipoise decisions
bout the value of adding SVR to CABG can be fully
haracterized. The purpose of this report is to profile the
isk spectrum of the STICH SVR hypothesis randomized
ohort to compare with that of the Society of Thoracic
urgeons (STS) STICH-eligible patients undergoing
ABG plus SVR by clinical choice using data entered
rospectively into the STS National Cardiac Database.
lacing STICH randomized patients in the clinical context
f patients treated by choice defines the degree to which the
esults of the STICH trial can be generalized to future
ecisions about adding SVR to CABG in patients with
schemic cardiomyopathy.
ethods
TICH patient enrollment and baseline clinical data
cquisition. Between September 12, 2002, and January 24,
006, 96 clinical sites randomized 1,000 patients to treat-
ent with CABG alone (n  499) or CABG plus SVR
n  501) (2). Four countries (Poland, n  288; the U.S.,
 200; Canada, n 154; and Italy, n 93) accounted for
35 of the 1,000 STICH SVR hypothesis patients (74%).
TICH clinical sites used standardized definitions to enter
tructured responses describing baseline clinical character-
stics of each randomized patient on pages 1, 2, and 4 of
TICH case report forms (5). Deficiencies, out-of-range
ntries, or conflicting answers were queried and corrected.
ites received reimbursement only for query-clean case
eport forms. Site-monitoring visits used primary source
ocuments to confirm the accuracy of data entered. Second-
ry SAS (SAS Institute Inc., Cary, North Carolina) data
nalysis files were formatted in tabular form.
Baseline clinical data were complete for 56 of 64 fields of
emographic and clinical data. Four of the 8 variables with
issing data were laboratory values for hemoglobin (n 2),
reatinine (n 2), sodium (n 4), and blood urea nitrogen
n  228). Coronary angiographic assessment of the prox-
mal left anterior descending coronary artery was unavailable
n 1 patient. History of renal insufficiency (creatinine 1.5
g/dl) was unavailable in 2 patients. History of hyperlip-
demia was unavailable in 3 patients. The initial protocol
equired reporting of a site-determined end-systolic volume
ndex. However, this assessment was not consistently
resent on cardiac catheterization reports. This require-
ent, which severely limited patient enrollment, was re-
oved (1). Site end-systolic volume index data were re-
orted for only 620 patients, but LVEFs were reported for
ll 1,000 patients. Percent akinesia or dyskinesia of the
nterior wall was reported in 577 STICH SVR hypothesis
atients. The STICH protocol version 2 permitted the
nrollment of patients using a site-determined LVEF
0.35 from echocardiography, cardiac magnetic resonance,ated single-photon emission computed tomography, or
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August 3, 2010:499–507 Surgical Ventricular Reconstructionontrast ventriculography. Each site was required to submit
n echocardiogram to the Echocardiography Core Labora-
ory. The submission of cardiac magnetic resonance and
ated single-photon emission computed tomographic ven-
riculograms for core laboratory reading was strongly en-
ouraged. The relationship of core laboratory cardiac imag-
ng study results to the primary STICH SVR hypothesis
utcome will be addressed in future reports. The LV
unctional and mitral regurgitation assessments described in
his report were those available to clinicians at the sites to
nform decisions about patient randomization. Only 693
atients performed 6-min walk tests at baseline, and symp-
oms during the tests were reported in 671 patients.
dentification of STS patients as STICH eligible. In
989, the STS created a voluntary database to support the
rospective entry of baseline clinical data on cardiac surgical
atients using standardized definitions. In 2002, SVR op-
rations were first entered separately from LV aneurysmec-
omy using the definition “procedure that restores the
eometry of the heart after an anterior myocardial infarc-
ion.” The SVR also was described as “distinct from an
nterior LV aneurysmectomy and from a Batista procedure
hat only produces LV volume reduction.”
To obtain STICH-eligible patients, the STS CABG
atabase was searched for patients with LVEFs 0.35 who
nderwent CABG during the 1,231-day STICH SVR
ypothesis patient enrollment interval and did not have the
TICH exclusion criteria of: 1) need for aortic valve
eplacement; 2) recent myocardial infarction; 3) concomi-
ant lung cancer resection; or 4) ongoing shock. STS
atients with operations coded as LV aneurysmectomy were
ot included. STS patients with LVEFs 0.10 also were
xcluded because of concern for spurious data. Of the
04,135 STS patients identified as STICH eligible, 103,043
99%) underwent CABG without SVR. After the exclusion
f 25 patients from the STS CABG plus SVR cohort who
ere also randomized into STICH and underwent CABG
lus SVR, 1,036 STS STICH-eligible patients (1%) under-
ent CABG plus SVR by choice. Although STS STICH-
ligible patients had baseline characteristics consistent with
TICH eligibility, the clinical choice of a CABG operation
rovides no evidence that these patients met the STICH
VR hypothesis entry criterion of dominant anterior akine-
ia or dyskinesia amenable to SVR. All STICH SVR
ypothesis patients could have been randomized to a
ABG plus SVR option. Baseline clinical characteristics
ere tabulated to compare the STS patients by operation
eceived by choice with those in the total 1,000-patient
TICH SVR hypothesis population.
isk at randomization (RAR) methodology. The RAR
ndex was developed to place randomized STICH patients
t their appropriate positions on the full spectrum of risk of
ll STICH patients (2). The application of STICH enroll-
ent criteria to patients in the Duke Databank for Cardio-
ascular Diseases (DDCD) produced a STICH-eligible
uke patient population from which multivariate modeling Ras developed to predict 5-year mortality, assuming absence
f surgical treatment. Baseline values for all prognostically
mportant variables of each STICH randomized patient
ere entered into the multivariate equation to predict their
-year mortality at the time of randomization. Patients were
laced in order of increasing predicted risk. An RAR index
as created to separate 32 groups that equally shared
ne-thirty-second of total predicted deaths using the con-
traint that the entire predicted mortality of each patient
as assigned to only 1 group. Individual values of baseline
haracteristics for each STS STICH-eligible CABG plus
VR patient were entered into the DDCD equation to
btain their predicted baseline mortality. This mortality was
sed to select the 32 STICH RAR groups with the high and
ow mortality window that encompassed the predicted
ortality for each of 1,036 STS STICH-eligible patients
ho received CABG plus SVR by clinical choice. The 9
TS patients with lower predicted mortality than any
TICH patient constituted RAR group 0, without STICH
atient representation. No STS patient had a higher pre-
icted mortality than STICH patients in RAR group 32.
TICH and STS STICH-eligible CABG plus SVR pa-
ients in each RAR group were assumed to share a suffi-
iently similar probability of death to serve as interchange-
ble couriers of baseline risk for clinical decision making.
ecause STS STICH-eligible patients who received CABG
y choice cannot be known to be SVR eligible, the risk
rofile methodology was applied only to STS patients
ndergoing CABG plus SVR by choice. Hereafter, this
,036-patient cohort of STS STICH-eligible CABG plus
VR patients is called the STS CABG plus SVR patients.
The risk profile of 499 STICH SVR hypothesis patients
ssigned to CABG without SVR is compared with that of
he 501 STICH SVR hypothesis patients assigned to
ABG plus SVR to assess the variability of the RAR
ethodology in these patients known to have no differences
t the p  0.05 level between the 2 treatment arms for any
ndividual baseline characteristic. The RAR profile of the
,000-patient STICH SVR hypothesis cohort was com-
ared with the risk profile of the 1,036 STS CABG plus
VR patients. Different representation of STICH and STS
ABG plus SVR patients was apparent in RAR groups 0 to
, 10 to 19, and 20 to 32. Baseline characteristics of STICH
nd STS CABG plus SVR patients in these 3 risk zones
ere tabulated separately to compare the magnitude of
ifferences in clinical characteristics responsible for the
bserved mismatch between the risk spectrum of the
TICH and STS CABG plus SVR cohorts. Finally, using
he Cox regression model, hazard ratios with 95% confi-
ence intervals were calculated for CABG plus SVR versus
ABG alone for the 391 STICH patients in RAR groups
to 9, 323 STICH patients in RAR groups 10 to 19, and
86 patients in RAR groups 20 to 32 to statistically test
hether there was a difference in the effect of CABG plus
VR compared with CABG depending on the baseline
AR.
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histogram of 1,000 STICH SVR hypothesis patients
orted by RAR index of increasing risk is compared with the
2 RAR interval values of selected baseline characteristics in
igure 1. The 64 lowest-risk patients in RAR group 1 had
median age of 49 years, a median LVEF of 0.31, and a
edian Duke coronary disease index of 39 (175% stenosis
ith either proximal left anterior descending stenosis or
0% to 75% left main stenosis). No patient had renal
nsufficiency (creatinine 1.5 mg/dl), 6 patients had mitral
egurgitation, and only 6 patients had diabetes. The 13
ighest-risk patients in the RAR group 32 had a median age
f 73 years, a median LVEF of 0.20, and a median Duke
oronary disease index of 91 (3 75% stenoses with either
95% proximal left anterior descending stenosis or 50%–
5% left main stenosis). All 13 RAR group 32 patients had
enal insufficiency, 4 patients had moderate or severe mitral
egurgitation, and 7 patients had diabetes. Moreover, severe
eart failure and vascular disease were more prevalent in this
ighest risk RAR group. These different combinations of
aseline cardiac and noncardiac variables explain the con-
inuous spectrum of increasing risk for the decreasing
umbers of patients assigned to each RAR interval.
The same RAR group was shared by 85% of the 499
ABG and 501 CABG plus SVR STICH patients (Fig. 2).
he 15% of unmatched patients distributed throughout the
ull RAR spectrum reflects the magnitude of statistical
ariation among the 32 groupings of patients known to have
o statistically significant difference of any single baseline
haracteristic (3).
The STICH randomized patients had clinical character-
stics suggesting them to be lower-risk patients than either
TS STICH-eligible population (Table 1). STICH pa-
ients were younger than the STS CABG cohort but similar
n age to the STS CABG plus SVR cohort. LVEFs were
.27 in STICH patients, 0.28 in the STS CABG cohort,
nd 0.24 in the STS CABG plus SVR cohort. The STICH
rial enrolled fewer women and fewer patients with periph-
ral vascular disease, multivessel coronary artery disease,
moking histories, stroke histories, and prior CABG than
ither STS cohort. Moderate or severe mitral regurgitation
as present in 18% of STICH patients, 16% of the STS
ABG cohort, and 30% of the STS CABG plus SVR
ohort.
The RAR profile of 1,000 STICH and 1,036 STS
ABG plus SVR patients showed that 1,522 of the 2,036
TICH and STS STICH-eligible patients (75%) shared
he same RAR group (Fig. 3). Because of 36 extra patients
n the STS cohort, the 761 matching STICH SVR hypoth-
sis patients represented 76% of their 1,000-patient cohort,
ut the 761 matching STS CABG plus SVR patients
epresented only 73% of the 1,036-STS patient cohort. The
bservation that only 10% more STS CABG plus SVR
atients failed to match STICH SVR hypothesis patients
han were observed to match between the 2 STICH SVR oypothesis randomized cohorts suggests similarity of the
TICH SVR hypothesis patients and the STICH random-
zed cohort. However, the mismatch identified more high-
isk patients in the STS cohort and more low-risk patients
n the STICH randomized patients.
Baseline clinical characteristics were compared for
TICH SVR hypothesis patients and the STS CABG plus
VR patients in RAR groups 0 to 9, RAR groups 10 to 19,
nd RAR groups 20 to 32 (Table 2). The difference in
atient baseline characteristics across the full risk spectrum
f either the STICH or the STS patient cohort was
ubstantially greater than the difference in baseline clinical
haracteristics between the STICH versus STS patient
ohorts within any of the 3 RAR groups. For example, the
ifference in age between low- and high-risk groups was a
ean of 13 years for STICH patients and a mean of 16
ears for STS CABG plus SVR patients. However, mean
ge was only 3 years higher for STICH patients in RAR
roups 0 to 9, 4 years higher for STICH patients in RAR
roups 10 to 19, and the same for both cohorts in RAR groups
0 to 32. The incidence of 3 or 4mitral regurgitation range
or low- and high-risk groups was 6% to 36% for STICH
atients and 8% to 45% for STS CABG plus SVR patients.
hese numeric changes are sufficient to explain greater num-
ers of high-risk STS CABG plus SVR patients but not
ufficient to invalidate the application of STICH results to
uture patient management decisions.
For the STICH SVR hypothesis primary outcome, Cox
odel hazard ratios and 95% confidence intervals compar-
ng STICH patients randomized to CABG plus SVR versus
ABG alone in RAR groups 1 to 9 (n  391), groups 10
o 19 (n  324), and groups 20 to 32 (n  285)
emonstrated no interaction between treatment and level of
aseline risk (Table 3). This evidence confirming the lack of
survival benefit from adding SVR to CABG over the
road spectrum of risk of the 1,000 SVR hypothesis patients
onfirms the previously reported STICH SVR hypothesis
onclusions to be broadly generalizable to patients with
schemic cardiomyopathy over the full range of STICH
VR hypothesis baseline risk. This conclusion will remain
mportant whether or not any core laboratory assessments of
lobal and regional LV function analyzed in the context of
ll clinical baseline variables subsequently are shown to
dentify patients who receive benefit from adding SVR to
ABG.
iscussion
inimization of treatment bias is the major advantage of a
andomized clinical trial over a well-conducted observa-
ional study. Drug safety and efficacy are tested incremen-
ally to define the population for whom use or nonuse of the
rug is safe and reasonable prior to conduct of large
andomized trials. In contrast, randomized trials of the
fficacy of operative procedures permit less standardization
f the treatment before evaluation. Operations designed to
503JACC Vol. 56, No. 6, 2010 Zembala et al.
August 3, 2010:499–507 Surgical Ventricular ReconstructionFigure 1 RAR Distribution of STICH SVR Hypothesis Patients C
Distribution of Values of Major Baseline Predictors of
Histogram of individual STICH (Surgical Treatment for Ischemic Heart Failure) surg
groups shows decreasing numbers of patients with increasing risk from RAR group
(CAD) index are depicted for each RAR group. The percentage of patients with bas
each RAR group. CR  creatinine; HF  heart failure; NYHA  New York Heart Asompared With
Risk for Each Interval
ical ventricular reconstruction (SVR) hypothesis patients by risk at randomization (RAR)
s 1 to 32. The median age, ejection fraction (EF), and Duke coronary artery disease
eline histories of specific cardiac and noncardiac disorders at baseline is depicted for
sociation.
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Surgical Ventricular Reconstruction August 3, 2010:499–507avorably alter pathophysiologic processes must first be
efined patient by patient so that the reason for performing
n operation and its technical conduct evolve iteratively
ntil it is considered to be indicated for selected patients as
linical practice. This evolutionary development of operative
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
424 (85%) of 499 Hypothesis 2 CABG patients match
424 (85%) of 501 Hypothesis 2 CABG+SVR patients 
Hypothesis 2
Patients
Randomized
to CABG
(n = 499)
Hypothesis 2
Patients
Randomized
to CABG+SVR
(n = 501)
75 (15%) of 499 Hypothes
not matched to Hypothesi
77 (15%) of 501 Hypothes
not matched to Hypothesi
40
30
20
10
0
10
20
30
40
Figure 2 RAR Profile of STICH SVR Hypothesis Patients Compa
Patients matched by randomized treatment assignment are plotted above in green
ized to CABG not matched by CABG plus SVR patients are plotted above in blue. P
are plotted below in red. Abbreviations as in Figure 1.
omparison of Baseline Characteristics of,000 STICH SVR Hypothesis Patients WithTS STICH-Eligible Patient Tre ed by Choiceith CABG or CABG Plus SVR
Table 1
Comparison of Baseline Characteristics of
1,000 STICH SVR Hypothesis Patients With
STS STICH-Eligible Patients Treated by Choice
With CABG or CABG Plus SVR
Variable
STS CABG
(n  102,964)
STICH SVR
Hypothesis
(n  1,000)
STS CABG
 SVR
(n  1,036)
Age (yrs) 65.7 11.0* 61.6 9.7 62.4 10.8
LVEF 27.9 6.5* 26.9 5.9 23.6 7.0*
Women 25%* 15% 21%*
Hypertension 77%* 59% 73%*
Peripheral vascular disease 21%* 15% 17%
Multivessel CAD 75% 97%* 80% 92%
Left main stenosis 0% 28%* 20% 15%†
Mitral regurgitation 3 16% 18% 30%*
Diabetes 44%* 34% 42%*
Smokers 29%* 22% 28%*
Myocardial infarction history 70%* 87% 83%†
Stroke history 9%* 6% 9%†
Prior CABG 7%* 2% 10%*
Atrial fibrillation/flutter 11% 12% 9%†
ata are expressed as mean  SD or %. *p  0.001; †p  0.05.
CABG  coronary artery bypass grafting; CAD  coronary artery disease; LVEF  left ventriculard
jection fraction; STICH Surgical Treatment for Ischemic Heart Failure; STS Society of Thoracic
urgeons; SVR  surgical ventricular reconstruction.rocedures rarely proceeds to the point of clear consensus
mong surgeons that randomized evaluation of a surgical
rocedure is needed. Moreover, the perceived value of an
peration may change over time. The earliest CABG
perations were performed to relieve angina (6,7). Now
ABG operations attempt to enhance coronary flow reserve
nd thereby decrease symptoms and increase patient sur-
ival. The earliest LV volume reduction operations were
esections of large, thin-walled saccular aneurysms to reduce
eart failure symptoms (8). As reperfusion therapy early in
he course of acute myocardial infarction decreased the size
nd transmural extent of myocardial injury, operative tech-
iques used for large saccular aneurysms have evolved to
ore effectively counter the deleterious geometric and
all stress effects of the scarred region on remote myo-
ardium (9 –12).
In 2001, the RESTORE group, composed of cardiolo-
ists and cardiac surgeons from 11 centers, reported on 439
atients undergoing SVR, with 89% also undergoing
ABG (13). The operation was defined as one that “reduces
entricular size by excluding the non-contracting segment
ith an intraventricular patch.” Operative mortality was
.6%. Only 27 patients were followed for 18 months, but
he Kaplan-Meier estimate of survival was 89% for that
nterval. Freedom from rehospitalization for heart failure
as 85% at 18 months. These investigators called for a
andomized trial of SVR. Despite the absence of outcome
6 17 18 19 20 21 22 23 24 25 26 27 28  29 30 31 32
ypothesis 2 CABG+SVR patients
d to Hypothesis 2 CABG patients
RAR Index
tients randomized to CABG
ents randomized to CABG+SVR
tients randomized to CABG+SVR
ents randomized to CABG
y Randomized Treatment Assignment
nary artery bypass grafting [CABG]) and below (CABG  SVR) 0. Patients random-
s randomized to CABG plus SVR not matched by patients randomized to CABG15 1
ed to H
matche
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atientata on a consecutive series of patients undergoing CABG
w
w
J
s
r
(
p
m
t
m
2
t
S
p
s
o
f
i
t
p
r
i
CS
D
505JACC Vol. 56, No. 6, 2010 Zembala et al.
August 3, 2010:499–507 Surgical Ventricular Reconstructionith and without SVR by choice, the editorialist agreed
ith the need for a randomized trial (14).
Hernandez et al. (15) reported the January 2002 to
anuary 2004 STS database enrollment of patients with LV
urgery using separate definitions for SVR and LV aneu-
ysm repairs. LV aneurysm repairs were performed in 2,436
77%) and SVR was performed in 731 (23%) of the 3,167
atients. The rate of reporting SVR grew from 15 patients/
onth in 2002 to 32 patients/month in 2004. Subsequent to
his report, SVR use has stabilized and was 32 patients/
onth for patients enrolled in the STS database during
008. During the 40.4-month STICH enrollment interval,
90
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0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1
STICH
Patients
STS
Patients
761 (76%) of 1000 STICH SVR hypothesis patients mat
239 (24%) of 1000 unmatche
275 (27%) of 1036 unmatche
761 (73%) of 1036 STS CABG + SVR patients matched
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tions as in Figures 1 and 2.
omparison of Baseline Clinical Characteristics in 3 Risk GroupingVR Hypothesis Patients (n  1,000) and STS CABG Plus SVR PatTable 2 Comp r son of Baseline Clinical Characteri tics in 3 RSVR Hypothesis Patients (n  1,000) and STS CABG P
Baseline Clinical Characteristic
Lowest-Risk Patients
(RAR Groups 0 to 9)
STICH Patients
(n  391)
STS Patients
(n  227)
Age (yrs) 55 8 52 8
LVEF 0.29 0.05 0.26 0.07
Women 52/391 (13%) 44/227 (19%)
Hypertension 211/391 (54%) 162/227 (71%)
Peripheral vascular disease 19/391 (5%) 11/227 (5%)
Multivessel CAD50% 328/391 (84%) 193/227 (85%)
Left main CAD50% 39/391 (10%) 21/227 (9%)
Mitral regurgitation3 21/362 (6%) 18/227 (8%)ata are expressed as mean  SD or as n (%).
RAR  risk at randomization; other abbreviations as in Table 1.he U.S. investigators enrolled 5 patients/month, whereas all
TS centers enrolled an average of 27 patients/month.
Demonstration that 75% of STICH and STS CABG
lus SVR patients in this report had similar baseline risk
uggests the STICH randomized cohort was representative
f the overall group of patients considered to be candidates
or CABG plus SVR during the time of STICH random-
zation. More unmatched STICH patients were present in
he low-risk RAR groups, and more unmatched STS
atients were present in the high-risk RAR groups. Hazard
atios that remain similar in patients grouped by low,
ntermediate, or high risk strongly indicate that no combi-
17 18 19 20 21 22 23 24 25 26 27 28  29 30 31 32 RAR Index
 STS patients
H SVR hypothesis patients
 patients
H SVR hypothesis patients
pared With 1,036 STS STICH-Eligible CABG Plus SVR Patients
o share the same RAR number are plotted from 0 (green). Excess STICH
t matched by STICH SVR hypothesis patients are plotted below in red. Abbrevia-
TICH(n  1,036)roupings of STICH
VR Patients (n  1,036)
Mid-Risk Patients
(RAR Groups 10 to 19)
Highest-Risk Patients
(RAR Groups 20 to 32)
ICH Patients
(n  324)
STS Patients
(n  289)
STICH Patients
(n  285)
STS Patients
(n  520)
64 8 60 9 68 8 68 9
.27 0.06 0.25 0.07 0.25 0.06 0.22 0.07
6/323 (17%) 68/289 (24%) 39/286 (14%) 112/520 (22%)
7/323 (61%) 213/289 (74%) 177/286 (62%) 395/520 (76%)
2/323 (16%) 32/289 (11%) 75/286 (26%) 133/520 (26%)
8/322 (96%) 271/289 (94%) 276/286 (97%) 513/520 (99%)
8/322 (21%) 52/289 (18%) 90/286 (32%) 88/520 (17%)
6/301 (15%) 65/289 (22%) 96/266 (36%) 237/520 (46%)5 16
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Surgical Ventricular Reconstruction August 3, 2010:499–507ation of baseline clinical variables with prognostic impor-
ance can reasonably be expected to help cardiac surgeons
dentify subgroups of patients who may benefit more from
VR added to CABG. However, the RAR index included
he clinical site LVEF as the only LV functional parameter.
egardless of whether or not subsequent reports of ongoing
ork using core laboratory data from preoperative cardiac
maging studies identify an LV function marker of differ-
ntial SVR treatment effect, the conclusion that no baseline
linical variable identifies any patient characteristic that
arks differential outcome of CABG with or without SVR
ill not change. Similarity of baseline clinical characteristics
f STICH and STS STICH-eligible patients confirms the
eneralizability of the STICH trial conclusions to patients
ith ischemic cardiomyopathy considered for CABG.
This report illustrates the enhanced value of the integra-
ion of information from both randomized trials and clinical
egistries. Clinical databases include cohorts of patients for
hom entry into a randomized clinical trial would not be
easonable. Randomized trial results illustrate the influence
f patient selection on variation in observed outcomes. For
xample, the operative mortality reported by Hernandez et
l. (15) was 9.3%, compared with 5.2% in STICH (3).
owever, analysis of this STS patient cohort as STICH
ligible would require elimination of data from emergency
atients and patients operated on by cardiac surgeons with
xperience performing 5 SVR operations. Data reported
y Hernandez et al. (15) suggest these STICH restrictions
pplied to STS patients would reduce the expected STS
perative mortality to 7.2%. Moreover, the magnitude of
ower baseline risk of STICH patients described in this
eport is adequate to explain the 2% lower operative mor-
ality observed in the STICH randomized cohort compared
ith the STS CABG plus SVR cohort.
tudy limitations. Definitions used to identify Duke pa-
ients as STICH eligible may have differed from those used
o identify STS STICH-eligible patients. Moreover, a
eparate STS CABG plus SVR patient multivariate equa-
ion was not developed and calibrated, so that the equation
eveloped on DDCD STICH-eligible patients may have
ad a consistent unrecognized bias when used to risk-profile
TICH and STS CABG plus SVR patients. Separate
atching of the Duke and STS patient selection definitions
o STICH patient entry definitions did permit the use of a
ingle multivariate equation to provide the predicted mor-
ality that linked STICH and STS CABG plus SVR
TICH SVR Hypothesis Assessment of CABG PlusVR Versus CABG in Subgroups Defined by RARTable 3 STICH SVR Hypothe is Ass ssment of CABG PlusSVR Versus CABG in Subgroups Defined by RAR
RAR Subgroup n Hazard Ratio (95% CI)
1–9 391 0.92 (0.69–1.22)
10–19 324 1.13 (0.85–1.51)
20–32 285 0.99 (0.75–1.31)
value for interaction  0.60.
CI  confidence interval; other abbreviations as in Tables 1 and 2.atients by their individual predicted mortality. This pre-icted mortality was used only to position each STICH
VR hypothesis and each STS CABG plus SVR patient
nto RAR groups defined by the same predicted risk ranges.
hat only 9 STS CABG plus SVR patients had lower
redicted mortality and none had higher predicted mortality
han any STICH randomized patient further suggests
ccuracy of risk profiling of these 2 patient populations.
Another limitation of the risk prediction used is that
atients were matched using mortalities calculated for pa-
ients as if they would not have cardiac surgery, but all
TICH SVR hypothesis and all STS patients were surgi-
ally treated. The purpose of this report was to link clinical
ecisions used to randomize STICH patients to the clinical
are decisions clinicians will make for future patients.
herefore, predicted risk was based on clinical information
vailable at a time when cardiac surgery was not yet certain
o be the treatment chosen, reflecting the way STICH trial
esults should be used to make future decisions about the
eed for adding SVR to future patients who are similar to
he STICH SVR hypothesis population.
onclusions
TICH patients randomized to CABG with or without
VR have baseline clinical risk more similar to STS CABG
lus SVR patients than STS CABG-only patients. The
AR profile shows a wide and similar range of risk for both
TICH SVR patients and STS patients treated by choice
ith CABG plus SVR. Although 75% of these 2 patient
ohorts shared the same RAR group, there were more
ow-risk STICH and more high-risk STS patients. Clinical
haracteristics responsible for these risk differences appear
o be of minimal clinical significance. Regression analysis
ased on Cox proportional hazards ratios showed no signif-
cant interaction with respect to survival. Ongoing analysis
ill assess whether any aspect of global or regional cardiac
unction assessed by core laboratory evaluation of baseline
ardiac images shows a different treatment effect of CABG
ith or without SVR with respect to the primary STICH
VR hypothesis outcome. The present study confirms the
esults of the STICH trial to be broadly generalizable to the
schemic cardiomyopathy population for whom CABG
ith SVR might be considered.
cknowledgment
he authors thank Vanessa Moore for her contributions to
his report and to the planning and conduct of STICH.
eprint requests and correspondence: Dr. Robert H. Jones,
uke University Medical Center, P.O. Box 2986, Durham, North
arolina 27710. E-mail: jones060@mc.duke.edu.
EFERENCES
1. Velazquez EJ, Lee KL, O’Connor CM, et al. The rationale and design
of the Surgical Treatment for Ischemic Heart Failure (STICH) trial.
J Thorac Cardiovasc Surg 2007;134:1540–7.
11
1
1
1
1
K
507JACC Vol. 56, No. 6, 2010 Zembala et al.
August 3, 2010:499–507 Surgical Ventricular Reconstruction2. Jones RH, White H, Velazquez EJ, et al. STICH (Surgical Treatment
for Ischemic Heart Failure) trial enrollment. J Am Coll Cardiol
2010;56:490–8.
3. Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass surgery
with or without surgical ventricular reconstruction. N Engl J Med
2009;360:1705–17.
4. Jones RH. Correspondence—surgical ventricular reconstruction.
N Engl J Med 2009;361:529–32.
5. STICH. Available at: http://www.stichtrial.org. Accessed June 25, 2010.
6. Kolessov VI. Mammary artery-coronary anastomosis as method of treat-
ment for angina pectoris. J Thorac Cardiovasc Surg 1967;54:535–44.
7. Favaloro RG. Saphenous vein graft in the surgical treatment of
coronary artery disease: operative technique. J Thorac Cardiovasc Surg
1969;58:178–85.
8. Cooley DA, Henly WS, Amad KH, Chapman DW. Ventricular
aneurysm following myocardial infarction: results of surgical treat-
ment. Ann Surg 1959;150:595–610.
9. Jatene AD. Left ventricular aneurysmectomy: resection or reconstruc-
tion. J Thorac Cardiovasc Surg 1985;89:321–31.
0. Dor V, Saab M, Coste P, Kornaszewska M, Montiglio F. Left
ventricular aneurysm: a new surgical approach. Thorac Cardiovasc
Surg 1989;37:11–9. t1. Ferrazzi P, Matteucci MLS, Merlo M, et al. Surgical ventricular
reverse modeling in severe ischemic dilated cardiomyopathy: the
relevance of the left ventricular equator as a prognostic factor. J Thorac
Cardiovasc Surg 2006;131:357–63.
2. Menicanti L, Castelvecchio S, Ranucci M, et al. Surgical therapy
for ischemic heart failure: single-center experience with surgical
anterior ventricular restoration. J Thorac Cardiovasc Surg 2007;
134:433– 41.
3. Athanasuleas CL, Stanley AWH Jr., Buckberg GD, et al. Surgical
anterior ventricular endocardial restoration (SAVER) in the dilated
remodeled ventricle after anterior myocardial infarction. J Am Coll
Cardiol 2001;37:1199–209.
4. Jones RH. Is it time for a randomized trial or surgical treatment of
ischemic heart failure? J Am Coll Cardiol 2001;37:1210–3.
5. Hernandez AF, Velazquez EJ, Dullum MKC, O’Brien SM, Ferguson
TB, Peterson ED. Contemporary performance of surgical ventricular
restoration procedures: data from the Society of Thoracic Surgeons’
National Cardiac Database. Am Heart J 2006;152:494–9.
ey Words: surgical ventricular reconstruction y randomized clinical
rial y mortality prediction y ischemic cardiomyopathy.
